SCHEMBL748910

SCHEMBL748910

CN1C2CCC1CC(Nc1cccc(-c3cccc4[nH]ccc34)c1)C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 1/20 0.43
CHRNA7 P36544 4/20 0.43
KCNH2 Q12809 2/20 0.43
ASH1L Q9NR48 1/20 0.42
ATR Q13535 1/20 0.41
HPGDS O60760 4/20 0.39
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
HTR3A P46098 1/20 0.39
HTR3D Q70Z44 1/20 0.39
HTR3C Q8WXA8 1/20 0.39
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
IDH2 P48735 1/20 0.39
PIK3CD O00329 3/20 0.39
ABL1 P00519 1/20 0.38
PIK3CB P42338 2/20 0.38
PIP4K2A P48426 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL748909 1.00 IRAK4 (0.43) IRAK4CHRNA7KCNH2ASH1LATR
Trifluoroacetic Acid SCHEMBL747098 0.91 HPGDS (0.39) IRAK4CHRNA7KCNH2ASH1LATR
Trifluoroacetic Acid SCHEMBL747097 0.91 HPGDS (0.39) IRAK4CHRNA7KCNH2ASH1LATR
SCHEMBL746815 0.89 CHRNA7 (0.45) IRAK4CHRNA7KCNH2ATRHPGDS
SCHEMBL746814 0.89 CHRNA7 (0.45) IRAK4CHRNA7KCNH2ATRHPGDS
SCHEMBL747644 0.87 HPGDS (0.53) IRAK4CHRNA7KCNH2ATRHPGDS
SCHEMBL747645 0.87 HPGDS (0.53) IRAK4CHRNA7KCNH2ATRHPGDS
SCHEMBL744578 0.81 NPC1 (0.45) IRAK4CHRNA7KCNH2ABL1
SCHEMBL744577 0.81 NPC1 (0.45) IRAK4CHRNA7KCNH2ABL1
Fumaric Acid SCHEMBL747078 0.81 CHRNA7 (0.41) IRAK4CHRNA7KCNH2ATRHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2431368-A1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives Abbott Laboratories (US) 2012-03-21 EP claimed
EP-2018380-B1 Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LAB (US) 2011-10-19 EP claimed
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives ABBOTT LABORATORIES (US) 2010-12-02 US claimed
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES ABBVIE INC. 2008-02-21 US claimed
US-8940762-B2 Methods for treating pain ABBVIE INC. (US) 2015-01-27 US disclosed
EP-2431368-A1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives Abbott Laboratories (US) 2012-03-21 EP disclosed
US-20110178121-A1 Methods for Treating Pain ABBOTT LABORATORIES (US) 2011-07-21 US disclosed
US-7872017-B2 Fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LABORATORIES (US) 2011-01-18 US disclosed
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives ABBOTT LABORATORIES (US) 2010-12-02 US disclosed
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES ABBVIE INC. 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES MALT1, BMP2, ALKBH2 IRAK4 2135/4885CHRNA7 2776/4885KCNH2 708/4885
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives MALT1, BMP2, ALKBH2 IRAK4 2135/4885CHRNA7 2776/4885KCNH2 708/4885
US-20110178121-A1 Methods for Treating Pain CHRNA7, CHRNA3, CHRNA5 IRAK4 1435/4885CHRNA7 1/4885KCNH2 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.